Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESIST: Resistance training to prevent muscle loss during tirzepatide treatment in adults with obesity
2026-526200-69-00Phase 4Authorised
- Sponsor
- Klinikum rechts der Isar
- Start
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tirzepatide in obesity (2 arms), sponsored by Klinikum rechts der Isar. Primary endpoint: Change in contractile thigh muscle volume. Planned start Aug 2026; status: authorised.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on 2026-526200-69-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526200-69-00.